论文部分内容阅读
[目的]观察升白汤口服液原方调整黄芪剂量改善化疗疗效及不良反应疗效。[方法]使用随机平行对照方法,将106例住院患者按病志号抽签方法简单随机分为三组。对照组A组30例TP方案化疗:紫杉醇175mg/m2,静脉滴注3h,1次/d;顺铂25mg/m2,D1~3L;紫杉醇化疗前30min行预处理:地塞米松10mg,静注,苯海拉明40mg,肌注,西咪替丁400mg,静滴。治疗组B组38例升白汤口服液(黄芪常规剂量),黄芪30g,白术、茯苓各15g,当归10g,太子参30g,女贞子、墨旱莲各15g,鸡血藤30g,水煎150~200m L,1剂/d,早晚温服,每程化疗前5d开始服用,连续14d。;西药治疗同对照组。治疗组C组38例升白汤口服液(黄芪调整剂量),黄芪20g,白术、茯苓各15g,当归10g,太子参30g,女贞子、墨旱莲各15g,鸡血藤30g,水煎150~200mL,1剂/d,早晚温服,每程化疗前5d开始服用,连续14d;西药治疗同对照组。连续治疗3周为1疗程。观测临床症状、血常规;治周血NK细胞活性、CD3+、CD 4+、CD8+、CD4+/CD8+、不良反应。连续治疗2疗程,判定疗效。[结果]A组CR2例,PR16例,SD5例,PD7例,DCR76.67%。B组CR3例,PR19例,SD11例,PD5例,DCR86.84%。C组CR3例,PR22例,SD10例,PD4例,DCR89.47%。B、C组疗效优于A组(P<0.05)。KPS评分、骨髓抑制、免疫功能B、C组优于A组(P<0.05),B组与C组无明显差异(P>0.05)。C组燥热症状改善优于B组(P<0.05)。[结论]升白汤口服液原方调整黄芪剂量对化疗疗效及不良反应改善,疗效满意,无严重不良反应,值得推广。
[Objective] To observe the original prescription of Shengbai decoction oral liquid and adjust the dose of Astragalus to improve the curative effect and adverse effect of chemotherapy. [Methods] Using randomized parallel control method, 106 inpatients were randomly divided into three groups randomly according to the method of lot drawing. Control group A group of 30 TP regimen chemotherapy: paclitaxel 175mg / m2, intravenous infusion 3h, 1 / d; cisplatin 25mg / m2, D1 ~ 3L; paclitaxel 30min before chemotherapy pretreatment: dexamethasone 10mg, intravenous injection , Diphenhydramine 40mg, intramuscular injection, cimetidine 400mg, intravenous infusion. Group B, 38 cases of treatment group Shengbai Tang oral solution (Astragalus conventional dose), Astragalus 30g, Atractylodes, Poria 15g, Angelica 10g, heterophylla 30g, Ligustrum lucidum 15g, Millettia 30g, decoction 150 ~ 200m L, 1 dose / d, morning and evening warm clothes, 5d before each course of chemotherapy began to take, continuous 14d. Western medicine treatment with the control group. Treatment group C 38 cases of Shengbai Tang oral (Astragalus dose adjustment), Astragalus 20g, Atractylodes, Poria 15g, Angelica 10g, heterophylla 30g, Ligustrum lucidum 15g, Millettia 30g, decoction 150 ~ 200mL, 1 dose / d, morning and evening warm clothes, taking 5d before each course of chemotherapy, continuous 14d; western medicine treatment with the control group. Continuous treatment for 3 weeks for a course of treatment. The clinical symptoms and blood routine were observed. The activity of NK cells in peripheral blood was measured, CD3 +, CD4 +, CD8 +, CD4 + / CD8 + and adverse reactions were observed. Continuous treatment of 2 courses to determine the efficacy. [Results] A group CR2 cases, PR16 cases, SD5 cases, PD7 cases, DCR76.67%. Group B CR3 cases, PR19 cases, SD11 cases, PD5 cases, DCR86.84%. C group CR3 cases, PR22 cases, SD10 cases, PD4 cases, DCR89.47%. The efficacy of group B and C was better than that of group A (P <0.05). KPS score, bone marrow suppression, immune function B, C group than the A group (P <0.05), B group and C group no significant difference (P> 0.05). Group C was better than the hot flaw in group B (P <0.05). [Conclusion] The prescription of Shengbai decoction orally adjusts the dose of Astragalus to the curative effect of chemotherapy and the improvement of adverse reactions, with satisfactory curative effect and no serious adverse reactions. It is worth popularizing.